Seegnal, акция обыкновенная (CA81573E1060, SEGN, 2I1)

Seegnal Inc., through its wholly owned subsidiary Seegnal eHealth Ltd. (Seegnal eHealth), is engaged in solving the causes of death and injuries in the modern world - Adverse Drug Effects (ADEs). Its Clinical Decision Support system introduces a paradigm shift in the approach to this problem by implementing a new elevated Patient-Centric Standard. Its SaaS technology integrates at the point-of-care, patient-specific data like genetics, results of lab tests, ECG, smoking, allergies, food, gender, age, and the effects of many concomitant medications, while reducing the alert load for clinicians by over 90%, by removing irrelevant alerts.

Its eHealth is marketing its SaaS-based platform in the State of Israel, the UAE, the United Kingdom, the United States, and Poland. The platform is a standard of care system for over 10,000 clinicians in Israel, used on a daily basis for prescribing medications to their patients.